- Active not recruitingPHASE1
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
This study is for adults with advanced cancer that hasn't responded to other treatments. It's testing new medicines, BI 770371 and ezabenlimab, to see how safe they are and what doses patients can comfortably take, hoping to help the immune system fight cancer.
For: Solid TumorsUnited States · Canada · Japan - Active not recruitingPHASE1
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
This study looks at new ways to treat advanced cancer. It tests a new drug, BI 765179, alone or with established treatments like ezabenlimab and pembrolizumab. We want to find out how safe these treatments are and if they can help people with different types of advanced cancer.
For: NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE1
A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer
This study for advanced pancreatic cancer tests a new treatment. It combines an immunotherapy (a protein alongside a virus that may kill cancer cells) with ezabenlimab, a drug that may boost your immune system. The aim is to find safe doses and see if it helps people live longer.
For: Pancreatic Ductal AdenocarcinomaUnited States · Germany · Spain - RecruitingPHASE1
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
This study looks at new treatments, BI 1703880 and Ezabenlimab, for different advanced cancers in adults when other treatments haven't worked. Doctors want to find a safe dose and see if these new drugs help the body fight cancer.
For: Solid TumorsUnited States · Japan · Spain - Active not recruitingPHASE1
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
This study looks at new ways to treat head and neck cancer. It combines different medicines that help your immune system fight cancer and stop tumours from growing. It's for people whose previous treatments weren't successful or who don't have standard options.
For: Head and Neck Squamous Cell Carcinoma (HNSCC)United States · France · Japan - AuthorisedTherapeutic exploratory (Phase II)
A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation
This study is looking at a new treatment called Ezabenlimab for a type of head and neck cancer. It focuses on patients who have small traces of cancer left after their first treatment, to see if adding Ezabenlimab can prevent the cancer from coming back.
For: Locally advanced head and neck squamous cell carcinoma (LA-HNSCC)Belgium